Alexander Muik,Bonny Gaby Lui,Ann-Kathrin Wallisch,Maren Bacher,Julia Mühl,Jonas Reinholz,Orkun Ozhelvaci,Nina Beckmann,Ramón de la Caridad Güimil Garcia,Asaf Poran,Svetlana Shpyro,Andrew Finlayson,Hui Cai,Qi Yang,Kena A. Swanson,Özlem Türeci,Uğur Şahin

Abstract:The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)–based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera